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ABSTRACT
Introduction Bariatric surgery offers the most effective 
treatment for obesity, ameliorating or even reverting 
associated metabolic disorders, such as type 2 diabetes. 
We sought to determine the effects of bariatric surgery 
on circulating microRNAs (miRNAs) that have been 
implicated in the metabolic cross talk between the liver 
and adipose tissue.
Research design and methods We measured 30 
miRNAs in 155 morbidly obese patients and 47 controls 
and defined associations between miRNAs and metabolic 
parameters. Patients were followed up for 12 months 
after bariatric surgery. Key findings were replicated in a 
separate cohort of bariatric surgery patients with up to 
18 months of follow- up.
Results Higher circulating levels of liver- related 
miRNAs, such as miR-122, miR-885-5 p or miR-192 
were observed in morbidly obese patients. The levels 
of these miRNAs were positively correlated with body 
mass index, percentage fat mass, blood glucose levels 
and liver transaminases. Elevated levels of circulating 
liver- derived miRNAs were reversed to levels of non- 
obese controls within 3 months after bariatric surgery. 
In contrast, putative adipose tissue- derived miRNAs 
remained unchanged (miR- 99b) or increased (miR-221, 
miR-222) after bariatric surgery, suggesting a minor 
contribution of white adipose tissue to circulating 
miRNA levels. Circulating levels of liver- derived miRNAs 
normalized along with the endocrine and metabolic 
recovery of bariatric surgery, independent of the fat 
percentage reduction.
Conclusions Since liver miRNAs play a crucial role in 
the regulation of hepatic biochemical processes, future 
studies are warranted to assess whether they may 
serve as determinants or mediators of metabolic risk in 
morbidly obese patients.
INTRODUCTION
Obesity is a chronic disease and widely 
recognized as the largest and fastest growing 
public health problem in the developed and 
developing world. The etiology of obesity 
is multifactorial but unhealthy human 
behavior, an obesogenic environment and 
inadequate healthcare advice are major 
contributors to the unprecedented increase 
in global overweight and obesity levels.1 
Obesity contributes to the onset of meta-
bolic disorders such as type 2 diabetes 
mellitus and non- alcoholic fatty liver disease 
(NAFLD).2 Although epidemiological 
correlations between obesity and insulin 
resistance in type 2 diabetes, NAFLD and 
Significance of this study
What is already known about this subject?
 ► Lipid and glucose homeostasis are controlled by 
a cross talk between the liver and adipose tissue. 
The molecular mechanisms of this cross talk remain 
unknown.
 ► Bariatric surgery is an effective treatment for obesity. 
It is currently unknown how it affects the liver–ad-
ipose tissue cross talk and the levels of microRNAs 
(miRNAs) in the circulation.
What are the new findings?
 ► Morbidly obese patients have elevated levels of cir-
culating liver- derived but not adipose tissue- derived 
miRNAs. Liver- derived miRNAs levels positively cor-
relate with body mass index, fat mass percentage 
and glucose levels.
 ► Bariatric surgery in obese patients restores the liver- 
derived miRNAs in serum to healthy levels.
 ► Circulating levels of adipose tissue- derived miRNAs 
are not reduced after bariatric surgery, despite a sig-
nificant weight loss. This refutes the hypothesis for 
a major contribution of adipose tissue to the circu-
lating miRNA pool.
How might these results change the focus of 
research or clinical practice?
 ► Further studies on the liver–adipose tissue cross talk 
are warranted with a focus on liver- derived miRNAs.
 ► Liver- derived miRNAs may be explored as biomark-
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metabolic syndrome are established, the cellular and 
molecular mechanisms that link obesity with metabolic 
disease remain less well explored.2 3
MicroRNAs (miRNAs, miR) are small non- coding 
RNAs that regulate gene expression at the post- 
transcriptional level.4 Circulating miRNAs are packaged 
in high- density lipoproteins,5 in protein complexes with 
argonaute 26 and other RNA- binding proteins7 as well 
as in extracellular vesicles (EVs), including exosomes.8 
Eukaryotic cells shed intact microvesicles from the 
cellular membrane and exosomes via the endosomal 
pathway.9 The composition and content of EVs vary 
depending on the parent cell from which they originate, 
as well as the cellular processes triggering their forma-
tion. It is proposed that exosomal miRNAs may be deliv-
ered to the recipient cells and participate in intercellular 
communication.10 11
There is a well- established cross talk between adipose 
tissue and the liver in terms of both lipid and glucose 
homeostasis. Recently, Thomou et al suggested that 
the principal source of exosomal miRNAs in the circu-
lation is the adipose tissue and that adipose- derived 
exosomal miRNAs can regulate hepatic gene expres-
sion.12 Furthermore, Zhao et al demonstrated that the 
levels of several EV miRNAs in the plasma of patients 
with NAFLD are positively correlated with body mass 
index (BMI), and these miRNAs enhance adipocyte 
lipid accumulation.13
So far, bariatric surgery offers the most effective and 
durable treatment for obesity ameliorating or even 
resolving comorbidities such as type 2 diabetes.3 14 15 It 
has been demonstrated in several randomized controlled 
trials that bariatric surgery achieves better glycaemic 
control and a higher rate of type 2 diabetes remission 
than the exclusive use of medication.16 Some studies 
have investigated the effects of obesity and bariatric 
surgery on the pattern of both circulating and adipose 
tissue miRNAs.17–21 However, the beneficial potential 
of bariatric surgery on circulating miRNAs remains 
unclear. The first miRNA which was found to be related 
to metabolic control was miR-122. It constitutes 70% of 
the total miRNA content in the liver, plays a central role 
in lipid metabolism and was reported to be secreted in 
exosomes.22 23 Our previous findings demonstrated a 
strong association of circulating liver- derived miR-122 
levels with the development of metabolic syndrome and 
type 2 diabetes.24 This association remained significant 
after multivariable adjustment, including BMI, waist–hip 
ratio and insulin resistance.24 It has been suggested that 
elevated levels of circulating miR-122 are reduced with 
weight loss and can be a marker of a harmful metabolic 
status.25
The objective of this study was to compare circulating 
levels of miRNAs in morbidly obese patients and healthy 
volunteers. Moreover, we analyzed miRNA levels in 
obese patients after undergoing bariatric surgery to 
establish its effects on circulating miRNAs.
RESEARCH DESIGN AND METHODS
Patients and sample collection
Serum samples were collected from healthy, non- obese 
patients (controls), and morbidly obese patients before 
and after they had undergone bariatric surgery, either 
Roux- en- Y gastric bypass (RYGB) or sleeve gastrectomy. 
For the bariatric surgery group in the discovery cohort 
from A Coruña (Spain), serum samples were taken on 
the day of bariatric surgery (n=155, T=0) and at various 
intervals after surgery. The follow- up time point at 
which the measurements were taken varied for different 
patients and was 3 months (n=29, T=3), 6 months (n=27, 
T=6) or 12 months (n=27, T=12) after bariatric surgery. 
For the validation cohort from Innsbruck (North Tyrol, 
Austria), stored serial serum samples were available from 
bariatric surgery patients with a BMI >40 kg/m2 before 
surgery (n=33, T=0) and 12 months (n=14, T=12) or 18 
months (n=19, T=18) after surgery, respectively. Consis-
tent with the discovery cohort, the validation cohort also 
had different follow- up time points for different patients.
Quantitative real-time PCR
Total RNA from murine serum (100 µL) was isolated with 
the miRNeasy Serum/Plasma Kit (Qiagen) according to 
the manufacturer’s instructions. Reverse transcription 
was then performed with the miRCURY LNA RT kit 
(Exiqon, catalog no: 339340) according to the manufac-
turer’s protocol. Real- time PCR was performed using the 
miRCURY Ready- to- Use PCR, Human panel I+II V1.M 
platform (Exiqon) on a ViiA 7 Real- Time PCR System 
with 384- well block. Relative miRNA expression was 
determined by the comparative cycle threshold (ΔΔCq) 
method by using the exogenous Caenorhabditis elegans 
spike- in control (cel- miR-39) for ΔCq and a calibrator 
consisting of an RNA pool of all samples for ΔΔCq.
Total RNA from patient serum (100 µL) was isolated with 
the miRNeasy Serum/Plasma Kit (Qiagen) according to 
the manufacturer’s instructions. RNA quality was deter-
mined by spectrophotometry in an ND-1000 NANO-
DROP 385 spectrophotometer (Thermo- Scientific). 
Three microliters of the extracted RNA was reverse tran-
scribed using Megaplex RT Primers, Human Pool Set 
v3.0 and TaqMan MicroRNA Reverse Transcription Kit 
(Applied Biosystems). Prior to quantitation by real- time 
PCR, 1 µL of undiluted RT product was preamplified 
using Megaplex PreAmp Primers along with the TaqMan 
PreAmp Master Mix (Applied Biosystems). After dilu-
tion of the sample, real- time PCR was performed using 
TaqMan Universal PCR Master Mix, No AmpErase UNG 
and specific primers to each miRNA on a ViiA 7 Real- Time 
PCR System with 384- well block. Relative miRNA expres-
sion was determined by the comparative ΔΔCq method 
by normalizing either to the C. elegans spike- in control 
(cel- miR-39) or to a global Cq average of 30 miRNAs: let- 
7b, miR-122- 5p, miR- 125a- 5p, miR- 130a- 3p, miR-140- 5p, 
miR-143- 3p, miR-145- 5p, miR- 148a- 3p, miR- 148b- 3p, 
miR-150- 5p, miR-191- 5p miR-192- 5p, miR- 19b- 3p, miR- 
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miR-222- 3p, miR-223- 3p, miR- 26a- 5p, miR- 27b- 3p, miR- 
29a- 3p, miR- 30b- 5p, miR-324- 5p, miR-486- 5p miR-375- 3p, 
miR-574- 3p, miR-885- 5p and miR- 99b- 5p.
Lepob mice
All procedures were performed in accordance with 
the Guidance on the Operation of the Animals (Scien-
tific Procedures) Act 1986 (UK) with ethical approval 
obtained from the local ethics committee (PPL: 70/8944 
to Professor Qingbo Xu). To determine whether miRNA 
profiles identified in bariatric patients also apply to 
hyperglycemic animals, we quantified miRNA levels in 
serum of obese mice. For this purpose, male Lepob mice 
aged 8–12 weeks (n=15, previously known as ob/ob) were 
purchased from Jackson Laboratories. Male C57BL/6J 
mice (n=15) were used as a control. Mice were kept on 
chow diet. A total of 1 mL of blood was harvested from 
each mouse at 14–15 weeks of age, and serum was isolated 
following clotting and centrifugation at 1200 g for 20 min 
at 4°C. Serum samples were aliquoted and stored at 
−80°C. All experiments were performed according to 
protocols approved by the Institutional Committee for 
Use and Care of Laboratory Animals.
Separation of EVs from murine serum
A differential centrifugation- based protocol was used to 
separate small EVs (sEVs), large EVs (lEVs) and super-
natant from mouse serum (wild type vs Lepob mice on 
C57BL/6J background, all mice aged 14–15 weeks, male 
and on normal diet).26 100 µL of serum were diluted to 
500 µL with phosphate- buffered saline (PBS) and centri-
fuged at 10 000 g for 30 min at 4°C. The pellet was resus-
pended in 100 µL PBS (=lEVs), while the supernatant 
was diluted to 1 mL with PBS and ultracentrifuged at 
1 00 000 g for 60 min at 4°C (Beckman Coulter Optima 
Max ultracentrifuge with TLA-55 rotor (k- Factor 89.5) 
and 9.5×38 mm Beckman Coulter Microcentrifuge Poly-
propylene Tubes). The supernatant was collected, and 
the pellet was resuspended in 1 mL PBS. Ultracentrifuga-
tion was then repeated using the same settings, and the 
supernatant was collected and added to the supernatant 
obtained from the previous step to a total volume of 2 mL 
(EV- depleted supernatant). The pellet was resuspended 
in 100 µL PBS (=sEVs). As expected, dot blot analysis 
confirmed that syntenin-1, a marker of sEVs, was enriched 
in the sEV isolates, while apolipoprotein B (ApoB), the 
integral membrane protein of APOB- containing lipopro-
teins, was depleted of sEV and lEV samples in compar-
ison to the EV- depleted fraction (online supplemental 
figure 1).
Data analysis
Relative quantification values of miRNAs and clinical 
variables for both discovery and validation cohorts were 
first filtered based on a missing value criterion. Specifi-
cally, miRNAs and clinical variables with more than 50% 
missing values were removed from the dataset and not 
considered for further analysis. For example, for T=3 
C reactive protein with 76% missing values, and ApoA1 
and ApoB with 83% missing values were not considered 
for further analysis. The miRNAs and clinical variables 
with less than 50% missing values were imputed using the 
KNN Impute algorithm.27 The imputation methodology 
was run separately for the different groups of the study. 
For example, for T=0 ApoA1 with 21% missing values 
was imputed. The limma package28 was used to compare 
between different phenotypes using the empirical Bayes 
algorithm29 and correcting for selected covariates. Paired 
analysis, ie, before and after surgery, was undertaken with 
correction for statin use to factor the change in medica-
tions of some patients after surgery. For control (healthy) 
and obese patients (ie before surgery, T=0), unpaired 
analysis was conducted. Unpaired analyses between 
healthy and obese participants were corrected for age, sex 
and statins. In all comparisons, the initial P values were 
adjusted for multiple testing using Benjamini- Hochberg 
method30 and a threshold of 0.05 was used for the 
adjusted P values to infer statistically significant changes. 
Spearman correlation was used for studying correlation 
patterns and continuous variables. Point- biserial correla-
tion31 was used for studying correlation patterns between 
miRNAs and categorical variables (such as sex and type 
2 diabetes). Linear regression analysis was performed to 
associate proteins with miR-122, and to relate miRNA 
changes after surgery with alterations in glucose, weight 
and liver transaminases, considering age, sex and statins 
as covariates and scaling values to zero means and SD of 
1. All figures were generated with R programming envi-
ronment and GraphPad software.
RESULTS
Differences in circulating miRNAs between obese patients 
and controls
We analyzed serum samples from morbidly obese patients 
before bariatric surgery (n=155) and from healthy partic-
ipants with normal BMI as controls (n=47). The clinical 
characteristics of all participants of this discovery cohort 
are shown in online supplemental table 1. A panel of 
30 circulating miRNAs previously associated with the 
liver or adipose tissue as well as unrelated blood cell- 
derived miRNAs were selected for analysis by quantita-
tive PCR. The most pronounced rise in morbidly obese 
patients was observed for miR-122, miR-885- 5p, miR- 148a 
and miR-210 (log2 fold change (FC) >1.5 and p<0.001). 
Levels of miR-150 were markedly decreased in obese 
patients compared with control individuals with normal 
BMI (figure 1A). The key findings based on standardized 
miRNA concentrations to the global Cq average were 
replicated using an exogenous spike- in miRNA, cel-miR-
39, for normalization (online supplemental figure 2). 
While miR-122 and liver- related miRNAs were among 
the most altered miRNAs, putative adipose tissue- derived 
miRNAs,12 32 33 that is, miR- 99b, miR-221 and miR-222, 
were detected at high levels in healthy human subcu-
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elevated in serum of morbidly obese patients (figure 1B). 
Using cel-miR-39 as an alternative normalisation strategy, 
miR-221 showed an increase (log2 (FC)=1.3, p=0.02), but 
it was relatively small in comparison to the liver- specific 
miR-122 (log2 (FC)=3.8, p<0.001) and liver- related 
miR-885- 5p (log2 (FC)=3.1, p<0.001) (online supple-
mental figure 3, online supplemental table 2).
Correlation analysis revealed distinct clusters with 
positive co- expression (figure 2A). The cluster with the 
most pronounced obesity- induced changes included 
liver- specific miR-122. Based on previous studies, as 
well as the human miRNA transcriptomic atlas, this 
cluster contained other abundant liver miRNAs, that is, 
miR-192 and miR-885- 5p.34 35 In a correlation analysis 
between baseline miRNAs levels with clinical variables 
in obese patients (figure 2B), miRNAs correlating with 
miR-122, such as miR-210, miR-192 and miR-885- 5p, 
but not miR-375, which is expressed in islet cells of the 
pancreas,36 were positively correlated with weight, BMI, 
percentage fat mass and glucose levels, and especially 
with liver transaminases, further supporting a relation-
ship between these serum miRNAs and liver dysfunction.
Circulating miRNA changes after bariatric surgery
Follow- up samples were available in a subset of patients 
from the discovery cohort at 3 months (n=29, T=3), 
6 months (n=27, T=6) and 12 months (n=27, T=12) 
after bariatric surgery. Bariatric surgery reduced the 
elevated serum levels of miR-122, miR-192, miR-885- 5p 
and miR-210 (figure 3; online supplemental tables 
3–5). In contrast, many blood cell- derived miRNAs, 
that is, miR-21,37 and putative adipose tissue- derived 
miRNAs12 32 33 were either unchanged, that is, miR- 99b, 
or even increased, that is, miR-221 and miR-222, after 
bariatric surgery (figure 3; online supplemental table 6). 
Again, miRNA concentrations that were standardized 
to the global Cq average (online supplemental table 6) 
were in agreement with results that used cel- miR-39 as 
an alternative normalization strategy (online supple-
mental table 7). Given a nearly 40% reduction in the 
average BMI after 12 months (from 49.6±0.62 before 
to 30.9±0.91 kg/m2 after bariatric surgery), our results 
suggest that adipose tissue may not be the main source 
of these circulating miRNAs.
To confirm our key findings, we performed further 
miRNAs measurements in an independent validation 
cohort of obese patients with samples before bariatric 
surgery (n=33) and at follow- up after 12 months (n=14) 
or 18 months (n=19), respectively. Their clinical char-
acteristics are shown in online supplemental table 8. A 
comparison of the results from the discovery and the 
validation cohort is presented in online supplemental 
table 9, confirming a significant reduction of circulating 
liver- derived miRNAs after bariatric surgery (online 
supplemental tables 10 and 11). In contrast, analysis of 
the putative adipose tissue- derived miRNAs showed no 
significant changes for miR- 99b, miR-222 and miR-221 
at either time point despite a pronounced and sustained 
weight loss over the 18 months of follow- up after bariatric 
surgery.
Figure 1 (A) Serum microRNAs (miRNAs) in obese patients and healthy controls. Volcano plot for differences in serum 
miRNAs between control (n=47) and obese patients (n=155) with standardized miRNA concentrations to the global Cq average. 
Statistical comparison was conducted using the empirical Bayes method of the limma package. P- values were corrected for 
multiple testing and are shown in blue, green, maroon for the different p- value ranges. Liver- specific miR-122 was among the 
miRNAs with the most elevated serum levels in obese patients compared with controls. (B) Bean plots for miRNAs normalized 
to the global Cq average. Bean plots showing elevated serum levels of liver- related (brown color) miR-122, miR-885-5 p and 
miR-192 in obesity. The serum levels of putative adipose tissue- related miRNAs (yellow color), such as miR- 99b, miR-221 and 
miR-222, were not elevated in obese patients. FC, fold change; NS, not significant. Protected by copyright.
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Compartmentalization of circulating miRNAs
Baseline levels of putative adipose tissue- derived miRNAs 
were lower in obese patients compared with non- obese 
controls, that is, miR- 99b and miR-222, or were not 
different, that is, miR-221. Moreover, circulating levels 
of miR- 99b did not change after bariatric surgery despite 
the substantial weight loss, while miR-221 and miR-222 
even increased after bariatric surgery. A possible expla-
nation for these results is that these serum miRNAs 
are either not adipose tissue- derived or adipose tissue- 
derived exosomes are not a major contributor to the total 
circulating miRNA content as suggested previously.12 To 
address the latter question, we harvested serum from 14 
to 15 week old wild type and obese- hyperglycemic Lepob 
mice and separated EVs by differential centrifugation. 
The profound increase of liver miRNAs observed in 
morbidly obese patients could independently be repli-
cated in serum samples of obese- hyperglycemic Lepob 
mice (figure 4A). Next, we conducted miRNA analysis 
in sEVs and lEVs as well as in the EV- depleted superna-
tant. Liver- derived miR-192- 5p and miR-122- 5p were 
predominantly detected in the EV- depleted superna-
tant. MiR-885- 5p was not included as this miRNA is not 
present in mice. For the putative adipose tissue- derived 
miRNAs, miR-221, miR- 99b and miR-222, their relative 
miRNA content in EVs was higher than liver- derived 
miRNAs (figure 4B), but there was no significant change 
in sEVs isolated from serum of Lepob mice compared 
with wild- type controls (online supplemental figure 4). In 
fact, a reduction of miR-221 and miR-222 was observed in 
lEVs from Lepob mice, in opposing direction to the corre-
sponding serum levels. Thus, EVs are a minor contrib-
utor to the circulating levels of these putative adipose 
tissue- derived miRNAs.
DISCUSSION
The circulating miRNAs that showed the most profound 
changes in morbidly obese patients formed a distinct 
co- expression cluster that included liver- specific miR-122, 
which correlated with body weight, BMI, percentage fat 
mass and liver transaminase levels. The observed drop 
of liver miRNAs within the first 3 months after bariatric 
surgery indicated a metabolic recovery following a time-
line correlating with the normalization of transaminase 
levels. At 3 months, the patients achieved on average a 
20% reduction in their BMI. Additional weight loss there-
after had no further effect on circulating levels of liver 
Figure 2 (A) Pairwise Spearman correlation of serum microRNA (miRNA) levels. Hierarchical clustering analysis and heat map 
matrix illustrating positive and negative co- expression and intracluster and intercluster relationships of pairwise comparisons 
of miRNAs before bariatric surgery. Only significant correlations are shown (p<0.05, normalized to the global Cq average). 
The sizes of the circles highlight the strength of correlation. Two distinct clusters emerge: one smaller cluster (brown color) 
is composed of liver- specific miR-122 and other liver- related miRNAs such as miR-885- 5p. The larger cluster (yellow color) 
contains a wide range of miRNAs from different cellular origins, including the putative adipose tissue- related miRNAs miR- 
99b, miR-221 and miR-222. (B) Correlations of serum miRNAs to clinical variables. Spearman correlation plot showing only 
significant correlations before bariatric surgery (p<0.05, normalized to the global Cq average). For the categorical variables 
sex and diabetes, point- biserial correlation was used. The cluster of liver- related miRNAs (highlighted in brown) is positively 
correlated (red color) with weight, BMI, percentage fat mass, blood glucose and liver transaminases. The different sizes of 
the circles highlight the strength of correlation. There was no positive association between BMI and percentage fat mass with 
serum levels of putative adipose tissue- related miRNAs, miR- 99b, miR-221 and miR-222. ALT, alanine aminotransferase; AST, 
aspartate aminotransferase; BMI, body mass index; DM, type 2 diabetes mellitus; fat mass (%), percentage fat mass; HDL- C, 
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miRNAs. In contrast, candidate adipose- derived miRNAs, 
such as miR- 99b, which Thomou et al12 suggested to be 
a previously undescribed form of adipokine, did not 
decline after bariatric surgery despite the dramatic 
weight loss after a 12–18- month follow- up.
Previous work reported higher miR-122, miR- 148a and 
miR-192 circulating levels in obesity.38 Altered blood 
miR-122 and miR-885- 5p levels have also been implicated 
in a variety of liver diseases, including drug- induced 
liver injury and NAFLD.39 40 Prevalence of NAFLD 
increases in parallel with obesity, metabolic syndrome 
and diabetes.41 42 In patients with NAFLD, miR-122 and 
miR-192 were among the most upregulated miRNAs in 
serum.43 Elevated miR-122 and miR-192 levels were also 
part of a plasma signature that predicted postopera-
tive liver dysfunction.44 Obese patients showed reduced 
levels of miR-122 1 year after RYGB while before surgery 
miR-122 circulating levels correlated with aspartate 
aminotransferase and alanine aminotransferase.45 Other 
circulating miRNAs that showed profound changes in 
our study have also been reported to increase with liver 
damage, that is, miR-210, miR- 148a, miR-143, miR-574, 
miR- 27b and miR- 200a.39 40 43 44 46
Thomou et al12 suggested a predominant adipose tissue 
origin of circulating exosomal miRNAs based on the use of 
adipose tissue- specific Dicer knockout (AdicerKO) mice. 
Dicer is required for the conversion of most, but not all 
pre- miRNAs to mature miRNAs.47 Liver- related miRNAs 
with profound changes after bariatric surgery, that is, miR- 
148a, miR-122, miR-210, were also decreased in exosomes 
from AdicerKO mice. In the study by Thomou et al,12 
exosomal miRNA profiling in patient serum returned 
only one miRNA, which was also found in our study to 
be significantly increased in obesity and reduced after 
bariatric surgery: miR-210 was upregulated in patients 
with congenital generalized lipodystrophy but not dysreg-
ulated in HIV- associated lipodystrophy (n=4 each and 
n=4 controls). To the best of our knowledge, the putative 
adipose tissue- derived miRNAs have not been measured 
in morbidly obese patients so far. Despite the fact that we 
detected high levels of adipose tissue- derived miRNAs in 
healthy human subcutaneous adipose tissue, the present 
data in morbidly obese patients refute that serum miRNAs 
are predominantly adipose tissue derived or that white 
adipose tissue- derived exosomes are a major contributor 
to the total circulating levels of miRNAs.
Figure 3 Effect of obesity and bariatric surgery on serum microRNA (miRNA) levels. Forest plots with the corresponding 
relative abundance ratios (log2- fold change, normalized to the global Cq average). Levels of miR-122, miR-885- 5p and miR-
192 fell within the first 3 months after bariatric surgery. These miRNAs were part of the cluster containing liver- related miRNAs 
(highlighted in brown color). At 3 months, patients achieved a reduction in body mass index (BMI) of approximately 20%. In 
contrast, miRNAs within the cluster containing the putative adipose tissue- related miRNAs (yellow color) showed no reduction 
even at 12 months of follow- up despite a reduction in BMI of almost 40%. The p- values are corrected for multiple testing and 
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One potential explanation for the discrepancy between 
our findings in morbidly obese patients and the ones 
reported by Thomou et al12 in AdicerKO mice is that 
brown adipose tissue is prominent in mice. Rodents and 
other small mammals have copious brown fat, whereas 
humans have very little after childhood.48 Thus, while 
liver miRNAs remain conserved across species, the 
composition of adipose- derived miRNAs, would be 
different between mice and humans. Given the analytical 
challenges and the lack of scalable methods to obtain 
pure vesicular preparations, we did not attempt to isolate 
EVs from human serum. However, the putative adipose 
tissue- derived miRNAs miR- 99b, miR-221 and miR-222 
showed no increase in the vesicle fractions of hypergly-
cemic Lepob mice. It should be noted that, although 
plasma concentrations of putative adipose- tissue derived 
miRNAs did not change with weight loss, changes in 
adipose tissue function could still affect circulating 
miRNAs. Dynamic changes in the production or removal 
of circulating miRNAs might not be reflected in static 
concentrations.
In summary, morbid obesity was associated with 
a profound increase in liver- derived miRNAs. The 
elevated serum levels of liver- derived miRNAs dropped 
within 3 months after bariatric surgery. This was asso-
ciated with a recovery of parameters related to liver 
dysfunction and reversal of type 2 diabetes, but not to 
further weight loss, suggesting that the main cause is 
a metabolic improvement rather than the loss of white 
adipose tissue.
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Supplemental Figure 2. Changes in serum miRNAs between control and obese patients normalized 
to cel-miR-39. 
Volcano plot for miRNA levels normalized to an exogenous miRNA, cel-miR-39, spiked in during RNA 
extraction. Statistical comparison was conducted using the e-bayes method of the limma package. P-
values were corrected for multiple testing and are shown in blue, green, maroon for the different p-
values ranges. Liver-specific miR-122 and liver-related miR-885-5p were amongst the miRNAs with 
the most elevated serum levels in obese patients (n=155) compared to controls (n=47). 
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Supplemental Table 1. Anthropometric and biochemical parameters of the discovery cohort. 
Values are expressed as mean ± SD. Serial adipose tissue samples were obtained from obese 
patients before and at various intervals after bariatric surgery i.e. 3, 6 and 12 months after surgery. 
T=0 indicates timepoint before surgery, T=3 indicates timepoint 3 months after surgery, T=6 
indicates timepoint 6 months after surgery and T=12 indicates timepoint 12 months after surgery. 
The follow-up measurement post-surgery was obtained at different intervals from different patients. 
Mann Whitney U-test and Fisher Exact test were used for the control vs obese comparison of the 
numerical and categorical clinical characteristics of the cohort respectively. Wilcoxon Signed rank 
test (paired analysis) and Fisher Exact test were used for the before and after surgery comparisons 
of the numerical and categorical clinical characteristics of the cohort, respectively. 
























Before and after surgery 
(3, 6, 12 months 
respectively) P-value 
 
Sample Size 47 155  29 27 28  
Sex 20♂, 27♀ 47♂, 108♀ 0.156 10♂, 
19♀ 
10♂, 
17♀ 7♂, 21♀  
Age (years) 39.7 ± 10.90 45.3 ± 9.21 <0.001 















(<0.001, <0.001, <0.001) 
BMI (kg/m
2







(<0.001, <0.001, <0.001) 










(<0.001, <0.001, <0.001) 
DM2 (%) 0% 36.10% <0.001 3.44% 7.41% 3.57% (<0.001, <0.001, <0.001) 
Anti-diabetic 
drugs (%)  
0% 35.48% <0.001 3.44% 7.41% 3.57% (<0.001, <0.001, <0.001) 
Anti-lipid 
drugs (%) 














(<0.001, 0.325, 0.070) 
HDL-C 
(mg/dL) 





































(0.885, <0.001, <0.001) 























(<0.001, <0.001, 0.003) 










(0.256, 0.0.564, 0.001) 







(0.239, 0.0025, <0.001) 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Diab Res Care














(0.023, <0.001, <0.001) 







(0.940, 0.007, 0.325) 
C-Peptide 
(ng/mL) 

































(<0.001, 0.052, 0.683) 







(0.025, 0.981, <0.001) 







(0.021, 0.027, 0.163) 







(0.045, <0.001, <0.001) 







(0.191, <0.001, 0.773) 







(0.405, 0.075, 0.203) 
BMI: body mass index, DM2: diabetes mellitus 2; T-Chol: total cholesterol, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density 
lipoprotein cholesterol, ALT: alanine aminotransferase, AST: aspartate aminotransferase, IGF-1: Insulin-like growth factor 1, GH: growth 
hormone, ApoA: Apolipoprotein A, ApoB: Apolipoprotein B, CRP: C-reactive protein, HbA1c: Glycated haemoglobin, HOMA-IR: homeostatic 
model assessment for insulin resistance, QUICKI: Quantitative insulin sensitivity check index, HICS: Hepatic Insulin Clearance Score 
calculated as the ratio of C-peptide to insulin.   
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Supplemental Table 2: Obese vs control comparison in the discovery cohort normalized to cel-miR-
39. 
Levels of miRNA were calculated in obese versus control participants (unpaired analysis) using the e-
bayes algorithm of the limma package and correcting for age, sex and statin uses. Adjustment of p-
values for multiple testing was conducted with Benjamini-Hochberg algorithm. In the table below, FC 
denotes fold-change; CIs denote limits of confidence interval for FC; AveExpr denotes average 
expression; t denotes moderated t-statistic; P.Value denotes raw p-value; adj.P.Value denotes 
adjusted p-value or q-value and B denotes log-odds that the miRNA is differentially expressed. 
 
  FC Low CI High CI AveExpr t P.Value adj.P.Val B 
miR-885-5p 8.70 5.59 13.55 0.00 9.64 0.00 0.00 30.84 
miR-122 13.79 7.27 26.15 0.11 8.08 0.00 0.00 20.99 
miR-148a 5.91 3.66 9.54 0.00 7.30 0.00 0.00 16.41 
miR-192 3.34 2.22 5.02 0.00 5.84 0.00 0.00 8.54 
miR-210 12.59 4.98 31.84 0.00 5.39 0.00 0.00 6.37 
miR-574 2.93 1.93 4.45 0.00 5.09 0.00 0.00 4.99 
miR-27b 4.55 2.38 8.68 0.00 4.62 0.00 0.00 2.98 
miR-145 2.46 1.68 3.61 0.00 4.62 0.00 0.00 2.98 
miR-150 0.57 0.45 0.73 0.01 -4.60 0.00 0.00 2.88 
miR-143 4.22 2.06 8.62 0.00 3.97 0.00 0.00 0.41 
miR-130a 1.64 1.28 2.10 0.00 3.96 0.00 0.00 0.39 
miR-200a 6.08 2.28 16.19 0.00 3.64 0.00 0.00 -0.76 
miR-223 2.22 1.28 3.86 0.50 2.86 0.00 0.01 -3.15 
miR-221 2.44 1.27 4.71 0.00 2.69 0.01 0.02 -3.60 
miR-29a 1.77 1.13 2.78 0.00 2.49 0.01 0.03 -4.09 
miR-148b 2.06 1.12 3.81 0.00 2.33 0.02 0.04 -4.48 
miR-140 1.69 1.03 2.76 0.00 2.10 0.04 0.07 -4.97 
miR-191 1.58 1.02 2.43 0.01 2.07 0.04 0.07 -5.02 
miR-21 1.32 0.95 1.82 0.02 1.67 0.10 0.15 -5.76 
miR-222 1.22 0.91 1.65 0.00 1.34 0.18 0.27 -6.26 
miR-324 1.90 0.67 5.34 0.00 1.22 0.22 0.32 -6.41 
miR-375 0.80 0.52 1.23 0.00 -1.01 0.32 0.43 -6.64 
miR-125a 1.42 0.69 2.93 0.00 0.96 0.34 0.44 -6.69 
miR-99b 1.14 0.73 1.79 0.00 0.58 0.56 0.70 -6.98 
miR-19b 1.11 0.69 1.79 0.11 0.44 0.66 0.79 -7.05 
let-7b 1.10 0.67 1.79 0.01 0.37 0.71 0.82 -7.08 
miR-486 1.06 0.72 1.57 0.02 0.30 0.77 0.85 -7.10 
miR-20b 0.96 0.59 1.55 0.00 -0.19 0.85 0.91 -7.13 
miR-26a 0.97 0.68 1.40 0.00 -0.16 0.88 0.91 -7.13 
miR-30b 1.00 0.75 1.35 0.00 0.02 0.98 0.98 -7.15 
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Supplemental Table 3: After surgery (3 months) vs Before surgery comparison in the discovery 
cohort normalized to cel-miR-39. 
Detailed results of the statistical comparison in the discovery cohort for miRNA levels 3 months after 
surgery and before bariatric surgery (paired analysis) using the e-bayes algorithm of the limma 
package and paired analysis correcting for statin use. Adjustment of p-values for multiple testing was 
conducted with the Benjamini-Hochberg algorithm. In the table below, FC denotes fold-change; CIs 
denote limits of confidence interval for FC; AveExpr denotes average expression; t denotes 
moderated t-statistic; P.Value denotes raw p-value; adj.P.Value denotes adjusted p-value or q-value 
and B denotes log-odds that the miRNA is differentially expressed. 
 
  FC Low CI High CI AveExpr t P.Value adj.P.Val B 
miR-122 0.18 0.09 0.37 0.03 4.99 0.00 0.00 2.44 
miR-192 0.25 0.14 0.46 0.00 4.70 0.00 0.00 1.68 
miR-210 0.08 0.02 0.43 0.00 3.08 0.00 0.05 -2.44 
miR-150 2.01 1.23 3.30 0.01 -2.89 0.01 0.06 -2.88 
miR-125a 0.08 0.01 0.66 0.00 2.43 0.02 0.11 -3.85 
miR-885-5p 0.25 0.08 0.81 0.00 2.41 0.02 0.11 -3.90 
miR-140 1.92 1.03 3.58 0.00 -2.13 0.04 0.18 -4.45 
miR-574 0.71 0.45 1.12 0.00 1.53 0.14 0.51 -5.44 
miR-27b 0.76 0.50 1.17 0.00 1.29 0.21 0.54 -5.76 
miR-30b 1.27 0.86 1.87 0.00 -1.27 0.21 0.54 -5.79 
miR-375 0.56 0.22 1.46 0.00 1.24 0.23 0.54 -5.83 
miR-191 1.35 0.80 2.29 0.01 -1.17 0.25 0.54 -5.91 
miR-222 1.20 0.87 1.67 0.00 -1.16 0.26 0.54 -5.92 
miR-324 2.52 0.46 13.89 0.00 -1.11 0.28 0.54 -5.97 
miR-26a 1.27 0.81 1.98 0.00 -1.09 0.28 0.54 -5.99 
miR-221 1.32 0.78 2.26 0.00 -1.08 0.29 0.54 -6.00 
miR-486 1.22 0.80 1.85 0.01 -0.97 0.34 0.60 -6.11 
let-7b 1.27 0.75 2.13 0.01 -0.93 0.36 0.60 -6.14 
miR-223 1.29 0.68 2.45 0.34 -0.81 0.42 0.67 -6.25 
miR-148b 1.58 0.44 5.70 0.00 -0.73 0.47 0.70 -6.31 
miR-20b 1.16 0.69 1.94 0.00 -0.57 0.57 0.77 -6.42 
miR-29a 0.89 0.59 1.36 0.00 0.55 0.59 0.77 -6.43 
miR-145 1.12 0.73 1.72 0.00 -0.55 0.59 0.77 -6.43 
miR-143 0.86 0.44 1.68 0.00 0.46 0.65 0.81 -6.48 
miR-19b 1.11 0.65 1.89 0.07 -0.39 0.70 0.84 -6.50 
miR-99b 1.12 0.53 2.35 0.00 -0.30 0.77 0.88 -6.54 
miR-130a 1.04 0.64 1.69 0.00 -0.16 0.87 0.96 -6.57 
miR-21 0.98 0.63 1.52 0.01 0.09 0.93 0.96 -6.58 
miR-148a 0.97 0.48 1.98 0.00 0.09 0.93 0.96 -6.58 
miR-200a 1.07 0.09 12.73 0.00 -0.05 0.96 0.96 -6.58 
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Supplemental Table 4: to After surgery (6 months) vs Before surgery comparison in the discovery 
cohort normalized to cel-miR-39. 
Detailed results of the statistical comparison in the discovery cohort for miRNA expression levels 6 
months after surgery and before bariatric surgery (paired analysis) using the e-bayes algorithm of 
the limma package and paired analysis correcting for statin use. Adjustment of p-values for multiple 
testing was conducted with the Benjamini-Hochberg algorithm. In the table below, FC denotes fold-
change; CIs denote limits of confidence interval for FC; AveExpr denotes average expression; t 
denotes moderated t-statistic; P.Value denotes raw p-value; adj.P.Value denotes adjusted p-value or 
q-value and B denotes log-odds that the miRNA is differentially expressed. 
  FC Low CI High CI AveExpr T P.Value adj.P.Val B 
miR-885-5p 0.08 0.04 0.16 0.00 7.60 0.00 0.00 8.09 
miR-192 0.25 0.14 0.45 0.00 4.85 0.00 0.00 1.50 
miR-122 0.09 0.03 0.26 0.01 4.84 0.00 0.00 1.48 
miR-150 1.78 1.27 2.50 0.00 -3.51 0.00 0.01 -1.78 
miR-221 3.01 1.49 6.06 0.00 -3.25 0.00 0.02 -2.40 
miR-26a 1.82 1.14 2.92 0.00 -2.64 0.01 0.07 -3.75 
miR-191 1.80 1.10 2.94 0.00 -2.47 0.02 0.09 -4.10 
miR-324 0.03 0.00 0.64 0.00 2.36 0.03 0.10 -4.32 
miR-210 16.54 1.34 204.54 0.01 -2.30 0.03 0.10 -4.43 
miR-223 1.77 1.00 3.15 0.15 -2.06 0.05 0.15 -4.88 
miR-30b 1.45 0.98 2.13 0.00 -1.96 0.06 0.17 -5.06 
miR-20b 1.66 0.92 2.99 0.00 -1.79 0.09 0.21 -5.35 
miR-375 0.47 0.20 1.13 0.00 1.77 0.09 0.21 -5.37 
miR-222 1.41 0.93 2.12 0.00 -1.72 0.10 0.21 -5.46 
miR-574 0.72 0.44 1.17 0.00 1.41 0.17 0.35 -5.92 
miR-140 1.46 0.81 2.60 0.00 -1.34 0.19 0.36 -6.01 
miR-99b 1.64 0.59 4.55 0.00 -1.01 0.32 0.49 -6.38 
miR-486 0.68 0.31 1.50 0.01 1.00 0.33 0.49 -6.39 
miR-29a 0.79 0.49 1.29 0.00 1.00 0.33 0.49 -6.39 
let-7b 1.28 0.77 2.14 0.00 -1.00 0.33 0.49 -6.39 
miR-130a 0.83 0.54 1.29 0.00 0.85 0.40 0.57 -6.53 
miR-143 0.42 0.05 3.80 0.00 0.82 0.42 0.58 -6.56 
miR-19b 1.19 0.72 1.98 0.03 -0.73 0.47 0.62 -6.63 
miR-27b 0.85 0.39 1.84 0.00 0.43 0.67 0.78 -6.80 
miR-200a 0.59 0.04 7.81 0.01 0.42 0.68 0.78 -6.80 
miR-21 0.92 0.61 1.39 0.01 0.40 0.69 0.78 -6.81 
miR-148b 1.45 0.18 11.71 0.00 -0.37 0.72 0.78 -6.83 
miR-145 1.08 0.68 1.72 0.00 -0.36 0.72 0.78 -6.83 
miR-125a 1.19 0.06 23.30 0.00 -0.12 0.91 0.94 -6.89 
miR-148a 1.00 0.45 2.21 0.00 0.00 1.00 1.00 -6.90 
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Supplemental Table 5: After surgery (12 months) vs Before surgery comparison in the discovery 
cohort normalized to cel-miR-39. 
Detailed results of the statistical comparison in the discovery cohort for miRNA levels 12 months 
after surgery and before bariatric surgery (paired analysis), using the e-bayes algorithm of the limma 
package and paired analysis correcting for statin use. Adjustment of p-values for multiple testing was 
conducted with the Benjamini-Hochberg algorithm. In the table below, FC denotes fold-change; CIs 
denote limits of confidence interval for FC; AveExpr denotes average expression; t denotes 
moderated t-statistic; P.Value denotes raw p-value; adj.P.Value denotes adjusted p-value or q-value 
and B denotes log-odds that the miRNA is differentially expressed. 
 
  FC Low CI High CI AveExpr T P.Value adj.P.Val B 
miR-122 0.09 0.05 0.15 0.02 9.38 0.00 0.00 12.28 
miR-885-5p 0.14 0.09 0.23 0.00 8.46 0.00 0.00 10.30 
miR-192 0.27 0.18 0.43 0.00 6.04 0.00 0.00 4.51 
miR-30b 1.78 1.29 2.45 0.00 -3.71 0.00 0.01 -1.41 
miR-26a 2.01 1.36 2.97 0.00 -3.68 0.00 0.01 -1.47 
miR-221 2.90 1.58 5.33 0.00 -3.61 0.00 0.01 -1.64 
miR-150 1.62 1.20 2.19 0.00 -3.30 0.00 0.01 -2.39 
miR-210 0.07 0.01 0.48 0.00 2.87 0.01 0.03 -3.39 
miR-148a 0.52 0.32 0.86 0.00 2.70 0.01 0.04 -3.77 
miR-191 1.76 1.11 2.80 0.01 -2.50 0.02 0.06 -4.18 
miR-99b 1.63 1.07 2.50 0.00 -2.36 0.03 0.07 -4.46 
miR-140 1.84 1.07 3.16 0.00 -2.32 0.03 0.07 -4.54 
miR-222 1.48 1.03 2.13 0.00 -2.21 0.04 0.08 -4.76 
miR-20b 1.83 1.04 3.23 0.00 -2.20 0.04 0.08 -4.79 
miR-223 1.62 0.95 2.74 0.29 -1.88 0.07 0.14 -5.36 
miR-19b 1.61 0.95 2.73 0.05 -1.84 0.08 0.15 -5.42 
let-7b 1.44 0.89 2.35 0.00 -1.55 0.13 0.24 -5.88 
miR-324 0.33 0.06 1.70 0.00 1.39 0.18 0.29 -6.10 
miR-21 1.24 0.86 1.77 0.01 -1.21 0.24 0.37 -6.32 
miR-130a 1.23 0.85 1.78 0.00 -1.17 0.25 0.38 -6.38 
miR-375 1.52 0.67 3.46 0.00 -1.04 0.31 0.44 -6.52 
miR-125a 0.54 0.09 3.27 0.00 0.71 0.49 0.63 -6.81 
miR-145 1.17 0.74 1.87 0.00 -0.70 0.49 0.63 -6.81 
miR-574 0.86 0.55 1.35 0.00 0.68 0.50 0.63 -6.82 
miR-27b 0.87 0.53 1.41 0.00 0.61 0.55 0.66 -6.87 
miR-148b 0.72 0.16 3.13 0.00 0.46 0.65 0.72 -6.95 
miR-143 0.70 0.14 3.54 0.00 0.46 0.65 0.72 -6.95 
miR-486 0.88 0.43 1.79 0.01 0.38 0.71 0.74 -6.99 
miR-200a 1.59 0.10 26.24 0.00 -0.34 0.73 0.74 -7.00 
miR-29a 0.93 0.58 1.49 0.00 0.33 0.74 0.74 -7.01 
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Supplemental Table 8. Anthropometric and biochemical parameters of the validation cohort. 
Values are expressed as mean ± SD. Serial adipose tissue samples were obtained from obese 
patients before and at various intervals after bariatric surgery i.e. 12, and 18 months after surgery. 
T=0 indicates timepoint before surgery, T=12 indicates timepoint 12 months after surgery, and T=18 
indicates timepoint 18 months after surgery. For 12 patients, the serial measurement was obtained 
12 months after surgery and for 19 patients, the serial measurement was obtained for 18 months 
after surgery. 
 Obesity T=0 Obesity T=12 Obesity T=18 
Sample Size 33 14 19 
Sex 9♂, 24♀ 0♂, 14♀ 9♂, 10♀ 
Age (years) 36.64 ± 9.54 40.36 ± 6.44 33.89 ± 10.59 
BMI (kg/m
2
) 42.37 ± 3.85 33.96 ± 5.20 33.44 ± 5.27 
T-Chol (mg/dL) 198.91 ± 38.89 191.07 ± 39.10 178.65 ± 32.95 
HDL-C (mg/dL) 49.04 ± 10.40 56.96 ± 15.30 48.13 ± 12.73 
LDL-C (mg/dL) 124.87 ± 34.93 115.05 ± 36.56 102.85 ± 33.04 
Triglycerides (mg/dL) 123.79 ± 48.66 103.14 ± 44.56 105.00 ± 53.05 
ALT (UI/L) 42.18 ± 33.89 17.50 ± 7.78 25.35 ± 10.59 
Insulin (µUI/L) 19.87 ± 14.82 12.48 ± 7.63 9.55 ± 5.27 
Fasting glucose (mg/dL) 97.94 ± 14.07 87.57 ± 7.78 97.82 ± 10.85 
CRP (mg/dL) 1.06 ± 0.92 0.69 ± 0.64 0.29 ± 0.35 
HbA1c (%) 5.74 ± 0.34 5.33 ± 0.15 Not Available 
HOMA-IR 4.46 ± 2.18 2.78 ± 1.95 2.25 ± 1.39 
 
BMI: body mass index, T-Chol: total cholesterol; HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, 
ALT: alanine aminotransferase; CRP: C-reactive protein, HbA1c: Glycated hemoglobin, HOMA-IR: homeostatic model assessment for insulin 
resistance.  
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Supplemental Table 10: After surgery (12 months) vs Before surgery comparison in the validation 
cohort normalized to the global CT average. 
Detailed results of statistical comparison in the validation cohort for miRNA levels 12 months after 
surgery and before bariatric surgery (paired analysis), using the e-bayes algorithm of the limma 
package and paired analysis. Adjustment of p-values for multiple testing was conducted with the 
Benjamini-Hochberg algorithm. In the table below, FC denotes fold-change; CIs denote limits of 
confidence interval for FC; AveExpr denotes average expression; t denotes moderated t-statistic; 
P.Value denotes raw p-value; adj.P.Value denotes adjusted p-value or q-value and B denotes log-
odds that the miRNA is differentially expressed. 
 
  FC Low CI High CI AveExpr t P.Value adj.P.Val B 
miR-122 0.36 0.23 0.57 1.54 -4.67 0.00 0.00 0.73 
miR-192 0.45 0.27 0.73 0.09 -3.46 0.00 0.03 -1.82 
miR-20b 2.07 1.03 4.14 0.60 2.20 0.04 0.25 -4.30 
miR-150 0.65 0.43 0.98 2.71 -2.19 0.04 0.25 -4.31 
miR-26a 1.70 0.99 2.93 0.88 2.05 0.06 0.27 -4.55 
miR-885-5p 0.37 0.12 1.16 0.21 -1.83 0.08 0.33 -4.91 
miR-29a 0.75 0.53 1.06 0.42 -1.76 0.10 0.33 -5.03 
miR-30b 1.45 0.89 2.36 2.07 1.60 0.13 0.37 -5.27 
miR-21 0.63 0.33 1.21 20.88 -1.49 0.15 0.37 -5.42 
let-7b 1.55 0.83 2.90 1.19 1.47 0.16 0.37 -5.44 
miR-145 1.40 0.86 2.28 1.39 1.43 0.17 0.37 -5.50 
miR-223 1.31 0.85 2.04 104.32 1.31 0.21 0.42 -5.66 
miR-148a 0.74 0.45 1.23 1.12 -1.24 0.23 0.43 -5.74 
miR-221 1.54 0.71 3.36 4.66 1.17 0.26 0.44 -5.82 
miR-143 1.35 0.70 2.61 0.18 0.97 0.34 0.55 -6.02 
miR-148b 1.36 0.67 2.78 0.28 0.91 0.37 0.56 -6.08 
miR-19b 0.70 0.25 1.94 29.47 -0.74 0.47 0.66 -6.22 
miR-222 0.91 0.63 1.33 3.40 -0.52 0.61 0.77 -6.36 
miR-574 1.21 0.55 2.66 0.82 0.52 0.61 0.77 -6.36 
miR-140 1.07 0.74 1.53 0.15 0.38 0.71 0.85 -6.42 
miR-375 1.14 0.42 3.11 0.11 0.27 0.79 0.89 -6.46 
miR-130a 0.95 0.55 1.64 5.77 -0.22 0.83 0.89 -6.47 
miR-27b 1.05 0.60 1.84 2.35 0.18 0.86 0.89 -6.48 
miR-99b 0.97 0.59 1.59 0.28 -0.14 0.89 0.89 -6.49 
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Supplemental Table 11: After surgery (18 months) vs Before surgery comparison in the validation 
cohort normalized to the global CT average. 
Detailed results of statistical comparison in the validation cohort for miRNA levels 18 months after 
surgery and before bariatric surgery (paired analysis), using the e-bayes algorithm of the limma 
package and paired analysis. Adjustment of p-values for multiple testing was conducted with the 
Benjamini-Hochberg algorithm. In the table below, FC denotes fold-change; CIs denote limits of 
confidence interval for FC; AveExpr denotes average expression; t denotes moderated t-statistic; 
P.Value denotes raw p-value; adj.P.Value denotes adjusted p-value or q-value and B denotes log-
odds that the miRNA is differentially expressed. 
 
  FC Low CI High CI AveExpr t P.Value adj.P.Val B 
miR-885-5p 0.45 0.27 0.74 0.85 -3.30 0.00 0.04 -1.72 
miR-223 1.52 1.16 1.99 142.95 3.23 0.00 0.04 -1.86 
miR-122 0.43 0.25 0.75 4.31 -3.16 0.00 0.04 -2.00 
miR-145 1.60 1.07 2.39 1.24 2.43 0.02 0.15 -3.45 
miR-221 1.82 0.99 3.35 2.61 2.03 0.06 0.28 -4.15 
miR-324 1.56 0.96 2.51 0.12 1.92 0.07 0.28 -4.33 
miR-574 1.32 0.95 1.85 0.96 1.74 0.10 0.31 -4.60 
miR-140 1.28 0.94 1.74 0.23 1.67 0.11 0.31 -4.70 
miR-143 1.74 0.87 3.46 0.11 1.66 0.11 0.31 -4.72 
miR-27b 1.50 0.79 2.85 1.00 1.32 0.20 0.46 -5.16 
miR-29a 1.19 0.89 1.59 0.44 1.27 0.22 0.46 -5.22 
miR-19b 1.17 0.90 1.51 21.34 1.26 0.22 0.46 -5.24 
miR-21 1.25 0.85 1.84 12.12 1.19 0.25 0.47 -5.31 
miR-192 0.81 0.55 1.20 0.16 -1.11 0.28 0.50 -5.40 
miR-148a 0.85 0.58 1.24 0.75 -0.89 0.38 0.60 -5.60 
miR-130a 1.17 0.81 1.67 1.20 0.89 0.38 0.60 -5.61 
miR-26a 1.18 0.73 1.90 1.25 0.71 0.49 0.68 -5.74 
miR-30b 1.15 0.75 1.76 2.25 0.67 0.51 0.68 -5.77 
miR-150 0.91 0.67 1.23 3.02 -0.66 0.51 0.68 -5.77 
miR-148b 1.27 0.50 3.24 0.06 0.52 0.61 0.76 -5.85 
miR-222 0.96 0.77 1.19 2.12 -0.41 0.68 0.78 -5.90 
miR-99b 1.07 0.71 1.61 0.35 0.34 0.74 0.78 -5.93 
let-7b 0.93 0.59 1.47 1.76 -0.33 0.74 0.78 -5.93 
miR-375 1.15 0.46 2.88 0.15 0.32 0.75 0.78 -5.94 
miR-20b 0.95 0.56 1.63 0.76 -0.18 0.86 0.86 -5.97 
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